Biopsies are limited
One tissue sample may not represent every lesion. Tumors can differ across the body and change over time.
Your access to molecular-based imaging and therapeutics - empowering precision oncology, led by worldwide experts.
Expert advisory support, working alongside your treating medical team.

A biopsy samples one place at one moment. Conventional scans show anatomy, but may not reveal the molecular differences between tumors or explain why a treatment is working in one lesion and not another.
One tissue sample may not represent every lesion. Tumors can differ across the body and change over time.
CT and MRI can track changes in tumor size, but may not show target expression or the biology behind resistance.
Blood-based tests can provide molecular clues, but do not always show where active disease or resistant lesions are located.
Whole-body, biomarker-based imaging can help reveal where specific molecular targets are expressed. Relit’s experts review your records and molecular data to identify relevant radioligand imaging (RLI) and radioligand therapy (RLT) options to discuss with your care team.
Our advisory work can include an initial case review, expert discussion, a written recommendations summary, logistical guidance, and introductions to relevant investigators or clinical programs. Ongoing support can include repeat scan reviews and monitoring emerging options.
Imaging and therapy suitability, availability, and access depend on your clinical situation. Some options are investigational; no particular scan, treatment, access, or outcome is guaranteed.
Our team brings experience in nuclear medicine, theranostics, radiochemistry, patient navigation, and precision oncology.

Chief Executive Officer
Healthcare executive and patient advocate with experience across digital health, biopharmaceuticals, medical devices, and single-patient treatment access.

Consulting Scientist
Experience developing monoclonal antibodies, peptides, lipid nanoparticles for mRNA delivery, and radioligand imagers and therapies, including work at LONZA and Stanford University.

VP, Patient Navigation & Scientific Discovery
Biomedical scientist and precision oncology leader with experience at Stanford and MD Anderson. Focused on molecular imaging, theranostics, molecular profiling, and individualized patient strategies.